A theranostic trial in prostate cancer participants, using 67Cu SAR-Bombesin therapy paired with the imaging agent, 64Cu SAR-Bombesin
Latest Information Update: 09 Jun 2022
At a glance
- Drugs 64Cu SAR bombesin-Clarity Pharmaceuticals (Primary) ; 67Cu SAR bisPSMA-Clarity Pharmaceuticals (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 09 Jun 2022 New trial record
- 06 Jun 2022 According to a Clarity Pharmaceuticals media release, the company anticipates to commence this trial in 2023.